Skip to content

Press Release · Press Releases

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Issued by PR Newswire

Image: PR Newswire

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

INVESTOR DEADLINE: Gildan Activewear Inc. Investors with Substantial Losses May Seek to Lead the Gildan Activewear Class Action Lawsuit Before December 14, 2026 Deadline - GIL

SAN DIEGO, Oct. 25, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Gildan Activewear Inc. (NYSE: GIL) publicly traded securities between February 19, 2025 and June 15, 2026, both dates inclusive (the "Class Period"), have...

PR Newswire ·